{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:58:05Z","timestamp":1780876685567,"version":"3.54.1"},"reference-count":0,"publisher":"American Diabetes Association","issue":"Supplement_1","license":[{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,7]]},"abstract":"<jats:p>Introduction and Objective: To evaluate the efficacy and safety of mazdutide (MAZ) 9 mg, a once-weekly GLP-1 and glucagon receptor dual agonist, in Chinese adults with obesity.<\/jats:p>\n                  <jats:p>Methods: In this randomized, double-blind, placebo (PBO)-controlled trial (NCT06164873, GLORY-2), 462 Chinese adults with obesity (BMI \u226530 kg\/m2; 16.0% with T2D) were randomized in a 2:1 ratio to receive once-weekly, subcutaneous MAZ 9 mg or PBO for 60 weeks. Co-primary endpoints were the percentage change in weight from baseline and a weight reduction (WR) of \u22655% at week 60.<\/jats:p>\n                  <jats:p>Results: At baseline, the mean body weight was 94.0 kg and the mean BMI was 34.3 kg\/m2. MAZ 9 mg met both co-primary endpoints and all key secondary endpoints. At week 60, the percentage change in body weight from baseline was-18.5 % with MAZ 9 mg, -3.0 % with PBO (treatment difference: -15.5% [95% CI:-17.6, -13.4]); 85.7% of participants with MAZ 9 mg, 33.2% with PBO achieved a WR of \u22655%; 44.0% of participants with MAZ 9 mg, 2.6% with PBO achieved a WR of \u226520%. For participants without T2D, the percentage change in body weight from baseline was -20.1 % with MAZ 9 mg, -2.8 % with PBO at week 60 (treatment difference: -17.3% [-19.6, -15.0]); 88.2% of participants with MAZ 9 mg, 32.3% with PBO achieved a WR of \u22655%; 48.7% of participants with MAZ 9 mg, 3.1% with PBO achieved a WR of \u226520% (P&amp;lt;0.001 for all comparisons). MAZ 9 mg also demonstrated significant improvements in blood pressure, lipids, and serum uric acid levels. MAZ was well tolerated, with AEs leading to treatment discontinuation reported in 2.9% of participants with MAZ 9 mg, and 0% with PBO. The most common AEs were gastrointestinal, mostly mild to moderate in severity.<\/jats:p>\n                  <jats:p>Conclusion: In Chinese adults with obesity, MAZ 9 mg provides clinically significant and superior weight loss compared with PBO, along with improvements in cardiometabolic risk factors and a favourable safety profile.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Disclosure<\/jats:title>\n                    <jats:p>L. Ji: None. L. Gao: Consultant; Current; Innovent Biologics, Inc. H. Jiang: Consultant; Current; Innovent Biologics. H. Cai: None. J. Tian: None. B. Shi: None. W. Qiu: None. Y. Wang: Employee; Current; Innovent Biologics, Inc. L. Li: Employee; Current; Innovent Biologics, Inc. Q. Ma: Employee; Current; Innovent Biologics. H. Deng: Employee; Current; Innovent Biologics, Inc. L. Pei: Employee; Current; Innovent Biologics, Inc. H. Han-Zhang: None. L. Qian: Employee; Current; Innovent Biologics, Inc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>Innovent Biologics, Inc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/db26-1225-or","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:01:30Z","timestamp":1780873290000},"update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":0,"title":["1225-OR: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Trial"],"prefix":"10.2337","volume":"75","author":[{"given":"LINONG","family":"JI","sequence":"first","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LEILI","family":"GAO","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HONGWEI","family":"JIANG","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HANQING","family":"CAI","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JUNHANG","family":"TIAN","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BIMIN","family":"SHI","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WEI","family":"QIU","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YANQI","family":"WANG","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LI","family":"LI","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QINGYANG","family":"MA","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HUAN","family":"DENG","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LIJUAN","family":"PEI","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HAN","family":"HAN-ZHANG","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LEI","family":"QIAN","sequence":"additional","affiliation":[{"name":"Changchun, China, Luoyang, China, Suzhou, China, Huzhou, China, Shanghai, China, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/75\/Supplement_1\/1225-OR\/167122\/1225-OR-Efficacy-and-Safety-of-Mazdutide-9-mg-in","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/75\/Supplement_1\/1225-OR\/167122\/1225-OR-Efficacy-and-Safety-of-Mazdutide-9-mg-in","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T23:01:31Z","timestamp":1780873291000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/75\/Supplement_1\/1225-OR\/167122\/1225-OR-Efficacy-and-Safety-of-Mazdutide-9-mg-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,7]]},"references-count":0,"journal-issue":{"issue":"Supplement_1","published-print":{"date-parts":[[2026,6,7]]}},"URL":"https:\/\/doi.org\/10.2337\/db26-1225-or","relation":{},"ISSN":["0012-1797"],"issn-type":[{"value":"0012-1797","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,7]]},"article-number":"1225-OR"}}